# Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

> **NCT07509008** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 10 (estimated)

## Conditions studied

- Gastric Cancer, Metastatic

## Interventions

- **DRUG:** TGFBR2 KO CAR27/IL-15 NK cells
- **DRUG:** Rimiducid (AP1903)
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07509008
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07509008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07509008, "Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07509008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*